Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | MAPT | P10636 | 4/20 | 0.41 |
| ▸ | TSHR | P16473 | 3/20 | 0.41 |
| ▸ | HTR7 | P34969 | 3/20 | 0.41 |
| ▸ | LMNA | P02545 | 3/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.38 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.38 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6097980 | 0.85 | KDM4E (0.36) | KMT2AKDM4EALDH1A1MAPTTSHR | |
| SCHEMBL6096487 | 0.81 | KDM4E (0.39) | KMT2AKDM4EALDH1A1MAPTTSHR | |
| SCHEMBL6099117 | 0.79 | HSD11B1 (0.40) | KMT2AKDM4EALDH1A1TSHRGAA | |
| SCHEMBL6096318 | 0.78 | KDM4E (0.35) | KMT2AKDM4EALDH1A1TSHRGAA | |
| SCHEMBL6095827 | 0.76 | RORC (0.35) | KMT2AKDM4EALDH1A1TSHRUSP2 | |
| SCHEMBL6096322 | 0.73 | CCR5 (0.43) | HTR7 | |
| SCHEMBL6096437 | 0.73 | HSD11B1 (0.47) | ALDH1A1MAPTHTR7LMNANPC1 | |
| SCHEMBL6098792 | 0.73 | SIGMAR1 (0.43) | — | |
| SCHEMBL6095524 | 0.73 | KDM4E (0.47) | KDM4EALDH1A1MAPTTSHRLMNA | |
| SCHEMBL6096963 | 0.72 | HTR7 (0.46) | KMT2AKDM4EALDH1A1TSHRHTR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040229864-A1 | Sulfone derivatives as 5-HT7 receptor ligands | MERCK SHARP & DOHME LTD. (GB) | 2004-11-18 | — | — | US | claimed |
| US-7101892-B2 | Sulfone derivatives as 5-HT7 receptor ligands | MERCK SHARP & DOHME LTD. | 2006-09-05 | — | — | US | disclosed |
| US-20040229864-A1 | Sulfone derivatives as 5-HT7 receptor ligands | MERCK SHARP & DOHME LTD. (GB) | 2004-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040229864-A1 | Sulfone derivatives as 5-HT7 receptor ligands | HTR7, HTR2C, HTR1A | MEN1 4149/4885KMT2A 2168/4885KDM4E 2306/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.